SYN - SYN STOCK NEWS

Synthetic Biologics, Inc. (NYSE American: SYN) will release its operational highlights and financial results for the quarter ended June 30, 2021, on August 5, 2021. The company is focused on developing microbiome therapeutics for gastrointestinal diseases with high unmet needs. Key candidates include SYN-004, aimed at preventing microbiome damage and infections, and SYN-020, targeting local and systemic GI diseases. A conference call is scheduled for the same day at 4:30 p.m. ET, with dial-in details included.

Synthetic Biologics, Inc. (NYSE American: SYN) completed patient dosing in its Phase 1 clinical trial for SYN-020, an intestinal alkaline phosphatase aimed at treating gastrointestinal diseases. The trial involved 24 healthy adults with doses from 5 mg to 150 mg. Preliminary data show SYN-020 had a favorable safety profile, with no serious adverse events reported. A second Phase 1 trial is set for Q3 2021, aiming to evaluate multiple-ascending doses, with topline results expected in Q2 2022. SYN-020 targets conditions like celiac disease and nonalcoholic fatty liver disease, catering to a significant market opportunity.

Synthetic Biologics, Inc. (NYSE American: SYN) announced on May 26, 2021, that it has regained compliance with NYSE American listing standards. This follows a previous notification regarding non-compliance due to insufficient stockholder equity. The Company reported stockholder equity of approximately $79.6 million in its most recent Form 10-Q. The '.BC' designation indicating non-compliance will be removed from the 'SYN' trading symbol, effective May 26, 2021. The Company focuses on developing microbiome-based therapeutics for gastrointestinal diseases.

Synthetic Biologics (NYSE American: SYN) announced the commencement of multiple clinical trials, including the Phase 1a trial of SYN-020 and the Phase 1b/2a trial of SYN-004. The company's cash position stands at approximately $76.9 million, bolstered by $8 million from warrant exercises. The cash runway extends into 2023, enabling funding for ongoing studies. Topline data for SYN-020 is expected in Q3 2021, while for SYN-004, it is anticipated in Q4 2021. The company reported a 32% decrease in R&D expenses to $1.1 million for Q1 2021.

Synthetic Biologics, Inc. (NYSE American: SYN) announced plans to release its operational highlights and financial results for Q1 2021 on May 5, 2021, followed by a conference call at 4:30 p.m. ET. The company focuses on leveraging the microbiome to develop therapeutics aimed at gastrointestinal (GI) diseases. Its lead candidates include SYN-004, intended to prevent microbiome damage and related infections, and SYN-020, designed to treat GI and systemic diseases.

Synthetic Biologics, Inc. (NYSE American: SYN) has initiated its Phase 1b/2a clinical trial of SYN-004 (ribaxamase) targeting acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic cell transplant recipients. The first patient has been dosed, and the trial aims to assess the safety and efficacy of SYN-004 in preserving gut microbiome integrity amid antibiotic treatment. A data readout for the first cohort is expected by the end of 2021. This trial is part of a broader strategy to establish SYN-004 as a vital therapeutic for high-risk patients.

Synthetic Biologics, Inc. (NYSE American: SYN) has commenced a Phase 1a clinical trial for SYN-020, a recombinant intestinal alkaline phosphatase (IAP), with six participants dosed. The trial aims to evaluate safety and pharmacokinetics in healthy volunteers. SYN-020 shows potential in treating gastrointestinal disorders, particularly celiac disease, which is projected to affect 4.3 million people in the U.S. by 2023. The company has addressed the high manufacturing costs of IAP, enabling viable clinical and commercial development. Topline results are expected in Q3 2021.

Synthetic Biologics (NYSE American: SYN) reported a clinical update and financial results for the year ended December 31, 2020. The company received IRB approval for the Phase 1b/2a clinical trial of SYN-004 targeting allogeneic hematopoietic cell transplant recipients. Current cash position stands at approximately $72.6 million, allowing funding into 2023. A decrease in R&D expenses to $5.1 million was noted, down 54.1% from the previous year. Upcoming milestones include patient dosing for SYN-004 in Q1 2021 and initial data readouts expected in late 2021.

Synthetic Biologics, Inc. (NYSE American: SYN) plans to announce its operational highlights and financial results for the year ending December 31, 2020, on March 4, 2021, at 4:30 p.m. ET. The call will provide insights into the company's clinical-stage developments in therapies targeting gastrointestinal diseases. Key treatments include SYN-004, aimed at preventing microbiome damage and infections, and SYN-020, an enzyme formulation for GI and systemic conditions. Investors can access the call via dial-in or live webcast, with a replay available for 90 days.